Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial - IMAG
Article Dans Une Revue RMD Open Année : 2023

Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial

Résumé

Objective Serum calprotectin appears to be an interesting biomarker associated with renal vascular disease activity in antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether serum calprotectin levels can predict decline in renal function in AAV patients receiving maintenance therapy. Methods Serum calprotectin levels were assessed at inclusion and month 6 in AAV patients, in complete remission after induction therapy, randomly assigned to rituximab or azathioprine. Renal function decline was defined as a 25% decrease in estimated glomerular filtration rate (eGFR) and a change in the eGFR category, or a decrease of 15 mL/min/1.73 m 2 . Relapse was defined as a Birmingham Vasculitis Activity Score >0 attributable to active vasculitis. Results Seventy-six AAV were included. Serum calprotectin increased from baseline to month 6 in patients with renal function decline (7940 (−226.0, 28 691) ng/ml vs −4800 (−18 777, 3708) ng/ml; p<0.001). An increase of calprotectin level was associated with a higher risk of subsequent renal function decline even after adjustment (OR 6.50 (95% CI 1.7 to 24.9) p=0.006). A significantly higher risk of relapse was observed in proteinase 3- AAV patients with an increase of serum calprotectin levels (OR 5.6 (95% CI 1.0 to 31.2), p=0.03). Conclusion An increase in serum calprotectin by month 6 compared with inclusion during remission-maintenance therapy in AAV was associated with a higher risk of renal function decline in the following 12 months. Trial registration number NCT00748644 .
Fichier principal
Vignette du fichier
e003477.full.pdf (433.47 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04724529 , version 1 (06-01-2025)

Identifiants

Citer

Xavier Romand, Marie Hélène Paclet, Minh Vu Chuong, Philippe Gaudin, Christian Pagnoux, et al.. Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial. RMD Open, 2023, 9 (4), pp.e003477. ⟨10.1136/rmdopen-2023-003477⟩. ⟨hal-04724529⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

More